Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13917735 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL13917736 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL4344384 | 0.97 | TDP1 (0.60) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL18586001 | 0.97 | TDP1 (0.60) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL1650142 | 0.97 | TDP1 (0.60) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL5983536 | 0.95 | TDP1 (0.57) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL9793504 | 0.95 | TDP1 (0.57) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL2933537 | 0.95 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL18105811 | 0.95 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL769397 | 0.95 | PDE4A (0.52) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| US-20230077014-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| WO-2022026960-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC (US) | 2022-02-03 | — | — | WO | claimed |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | Natural Extraction Systems, LLC | 2021-11-25 | — | — | US | claimed |
| WO-2021158714-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158574-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| US-20240229046-A1 | ENGINEERED BIOSYNTHETIC PATHWAYS FOR PRODUCTION OF DEOXYHYDROCHORISMIC ACID BY FERMENTATION | ZYMERGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-11618880-B2 | Compositions comprising bacterial strains and use thereof in controlling pathogenic microorganisms | BETTER AIR INTERNATIONAL LIMITED (HK) | 2023-04-04 | — | — | US | disclosed |
| US-20230077014-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| US-7863032-B2 | Bacillus licheniformis chromosome-encoded endoglucanase | NOVOZYMES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20090275104-A1 | Bacillus licheniformis chromosone | NOVOZYMES A/S (DK) | 2009-11-05 | — | — | US | disclosed |
| US-7494798-B2 | Bacillus licheniformis chromosome | NOVOZYMES, INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080050774-A1 | Computer-based system for monitoring differential expression; host cells | NOVOZYMES A/S (DK) | 2008-02-28 | — | — | US | disclosed |
| EP-1066309-A4 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1066309-A1 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORPORATION (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999051620-A1 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885LMNA 1219/4885L3MBTL1 448/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885LMNA 1219/4885L3MBTL1 448/4885 |
| US-20210360947-A1 | COMPOSITIONS AND METHODS RELATED TO EXCIPIENTS AND CANNABINOID FORMULATIONS | CNR2, CNR1, FAAH | PDE4A 2022/4885LMNA 1759/4885L3MBTL1 4875/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | PDE4A 4587/4885LMNA 1219/4885L3MBTL1 448/4885 |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR2, CNR1, FAAH | PDE4A 2146/4885LMNA 1799/4885L3MBTL1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.